BioNTech SE (BNTX)

BioNTech SE Statistics

Total Valuation

BioNTech SE has a market cap or net worth of $25.18 billion. The enterprise value is $8.07 billion.

Market Cap	25.18B
Enterprise Value	8.07B

Important Dates

The next confirmed earnings date is Monday, May 5, 2025, before market open.

Earnings Date	May 5, 2025
Ex-Dividend Date	n/a

Share Statistics

BioNTech SE has 239.97 million shares outstanding. The number of shares has decreased by -0.95% in one year.

Current Share Class	n/a
Shares Outstanding	239.97M
Shares Change (YoY)	-0.95%
Shares Change (QoQ)	-1.75%
Owned by Insiders (%)	18.80%
Owned by Institutions (%)	22.48%
Float	92.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.86
Forward PS	9.63
PB Ratio	1.25
P/TBV Ratio	1.33
P/FCF Ratio	n/a
P/OCF Ratio	117.11
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	2.83
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.01.

Current Ratio	7.45
Quick Ratio	7.26
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-102.02

Financial Efficiency

Return on equity (ROE) is -3.36% and return on invested capital (ROIC) is -4.00%.

Return on Equity (ROE)	-3.36%
Return on Assets (ROA)	-3.53%
Return on Invested Capital (ROIC)	-4.00%
Return on Capital Employed (ROCE)	-6.43%
Revenue Per Employee	$420,588
Profits Per Employee	-$101,711
Employee Count	6,772
Asset Turnover	0.12
Inventory Turnover	1.69

Taxes

Income Tax	-12.84M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +16.67% in the last 52 weeks. The beta is 1.08, so BioNTech SE's price volatility has been similar to the market average.

Beta (5Y)	1.08
52-Week Price Change	+16.67%
50-Day Moving Average	101.77
200-Day Moving Average	106.43
Relative Strength Index (RSI)	53.20
Average Volume (20 Days)	1,503,981

Short Selling Information

Short Interest	4.34M
Short Previous Month	3.63M
Short % of Shares Out	4.70%
Short % of Float	n/a
Short Ratio (days to cover)	4.17

Income Statement

In the last 12 months, BioNTech SE had revenue of $2.85 billion and -$688.79 million in losses. Loss per share was -$2.87.

Revenue	2.85B
Gross Profit	2.29B
Operating Income	-1.33B
Pretax Income	-269.98M
Net Income	-688.79M
EBITDA	-1.07B
EBIT	-1.33B
Loss Per Share	-$2.87

Balance Sheet

The company has $17.38 billion in cash and $263.17 million in debt, giving a net cash position of $17.11 billion or $71.31 per share.

Cash & Cash Equivalents	17.38B
Total Debt	263.17M
Net Cash	17.11B
Net Cash Per Share	$71.31
Equity (Book Value)	20.10B
Book Value Per Share	83.75
Working Capital	16.86B

Cash Flow

In the last 12 months, operating cash flow was $215.03 million and capital expenditures -$296.61 million, giving a free cash flow of -$89.06 million.

Operating Cash Flow	215.03M
Capital Expenditures	-296.61M
Free Cash Flow	-89.06M
FCF Per Share	-$0.37

Margins

Gross margin is 80.32%, with operating and profit margins of -46.73% and -24.18%.

Gross Margin	80.32%
Operating Margin	-46.73%
Pretax Margin	-24.63%
Profit Margin	-24.18%
EBITDA Margin	-37.55%
EBIT Margin	-46.73%
FCF Margin	n/a

Dividends & Yields

BioNTech SE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.95%
Shareholder Yield	n/a
Earnings Yield	-2.74%
FCF Yield	-0.35%

Analyst Forecast

The average price target for BioNTech SE is $145.88, which is 39.01% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$145.88
Price Target Difference	39.01%
Analyst Consensus	Strong Buy
Analyst Count	17
Revenue Growth Forecast (5Y)	4.83%
EPS Growth Forecast (5Y)	-19.52%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

BioNTech SE has an Altman Z-Score of 6.17 and a Piotroski F-Score of 2.

Altman Z-Score	6.17
Piotroski F-Score	2